LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
-251.6%+1196.8 pts over 5 years
Net margin
-436.5%+694.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +53.2% | -0.3% | +51.5% | +7.5% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 46.7% | -19.7% | -103.4% | |
| Return on assets | 28.3% | -17.7% | -56.3% | |
| Current ratio | 2.90 | 5.66 | 5.20 | |
| Debt to equity | 0.00 | – | – | |
| Net debt to EBITDA | 0.38× | – | – | |
| Capex to revenue | 38.0% | 3.5% | 3.6% | |
| Diluted shares | 100M | 0M | 230M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Lineage Cell Therapeutics generated $95.20M from operations and spent $2.51M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$95.20M
Used
$2.51M
Capital expenditure$2.51M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-436.5%
×Asset turnover0.13×
×Equity multiplier1.84×
=Return on equity, FY2025-103.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -436.5% | 0.13× | 1.84× | -103.4% |
| FY2024 | -195.9% | 0.09× | 1.51× | -26.2% |
| FY2023 | -240.2% | 0.08× | 1.64× | -31.4% |
| FY2022 | -178.7% | 0.10× | 1.80× | -31.7% |
| FY2021 | -991.0% | 0.03× | 1.50× | -45.7% |
| FY2020 | -1130.8% | 0.02× | 1.12× | -19.7% |
| FY2019 | -333.1% | 0.03× | 1.11× | -11.4% |
| FY2018 | -922.0% | 0.04× | 1.08× | -36.1% |
| FY2017 | -577.7% | 0.02× | 1.13× | -14.2% |
| FY2016 | 566.8% | 0.05× | 1.65× | 46.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$63.53M
- Cash generatingOperating cash flow above zero-$18.92M
- Return on assets improvedROA up on the prior year-18.4% → -56.1%
- Earnings backed by cashOperating cash flow above net income-$18.92M vs -$63.53M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.65 → 5.20
- No dilutionShare count did not rise200M → 230M
- Gross margin improvedGross margin up on the prior year96.48% → –
- More efficientAsset turnover rose0.09 → 0.13